Cargando…

Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study

BACKGROUND: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trials have demonstrated significant kidney benefits with sodium-glucose cotransporter-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Tae Won, Atiquzzaman, Mohammad, Zheng, Yuyan, Smyth, Brendan, Jardine, Meg, Levin, Adeera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Clinical Research Quantitative
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791275/ https://www.ncbi.nlm.nih.gov/pubmed/36578697 http://dx.doi.org/10.1177/20543581221145068

Ejemplares similares

Prescription Pattern of Cation Exchange Resins and Their Efficacy in Treating Chronic Hyperkalemia Among Patients With Chronic Kidney Diseases: Findings From a Population-Based Analysis in British Columbia, Canada
por: Atiquzzaman, Mohammad, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
por: Neuen, Brendon L, et al.
Publicado: (2020)

A Provincial Survey of the Contemporary Management of Autosomal Dominant Polycystic Kidney Disease
por: Yi, Tae Won, et al.
Publicado: (2020)

Trajectories of Nutritional Parameters Before and After Prescribed Oral Nutritional Supplements: A Longitudinal Cohort Study of Patients With Chronic Kidney Disease Not Requiring Dialysis
por: Wong, Michelle M. Y., et al.
Publicado: (2022)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Performance of StatSensor Point-of-Care Device for Measuring Creatinine in Patients With Chronic Kidney Disease and Postkidney Transplantation
por: Nataatmadja, Melissa, et al.
Publicado: (2020)

Workplace and non-workplace cannabis use and the risk of workplace injury: Findings from a longitudinal study of Canadian workers
por: Carnide, Nancy, et al.
Publicado: (2023)

Socioeconomic position and consumption of sugary drinks, sugar-sweetened beverages and 100% juice among Canadians: a cross-sectional analysis of the 2015 Canadian Community Health Survey–Nutrition
por: Warren, Christine, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness in patients with non–dialysis-dependent chronic kidney diseases: findings from a population-based observational study from British Columbia, Canada
por: Atiquzzaman, Mohammad, et al.
Publicado: (2022)

Determinants of non-vaccination against seasonal influenza in Canadian adults: findings from the 2015–2016 Influenza Immunization Coverage Survey
por: Farmanara, Noushon, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients
por: Lai, Elaine F., et al.
Publicado: (2022)

Weight, Weight Perceptions, and Health and Well-Being Among Canadian Adolescents: Evidence From the 2017-2018 Canadian Community Health Survey
por: Chai, Lei, et al.
Publicado: (2021)

Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats
por: Kapoor, Sarika, et al.
Publicado: (2015)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
por: Dekkers, Claire C J, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
por: Jo, Hyung Ah, et al.
Publicado: (2023)

Risk Factors for First and Recurrent Fractures among Kidney Transplant Recipients
por: Atagu, Norman, et al.
Publicado: (2022)

Workplace exposure to asbestos and the risk of kidney cancer in Canadian men
por: Peters, Cheryl E., et al.
Publicado: (2018)

Disparities in Deceased Donor Kidney Offer Acceptance: A Survey of Canadian Transplant Nephrologists, General Surgeons and Urologists
por: Vinson, A. J., et al.
Publicado: (2023)

Canadian Newspaper Coverage of the A/H1N1 Vaccine Program
por: Rachul, Christen M., et al.
Publicado: (2011)

Correlations between weight perception and overt risk-taking among Canadian adolescents
por: Bartlett, Sydney, et al.
Publicado: (2023)

A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
por: Kume, Shinji, et al.
Publicado: (2022)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
por: Oliveras, Laia, et al.
Publicado: (2023)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
por: Hsieh, Cheng-Yang, et al.
Publicado: (2022)

Evaluating the Manitoba Infant Feeding Database: a Canadian infant feeding surveillance system
por: Paul, Julia A., et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?
por: Burnier, Michel
Publicado: (2021)

Variability in ambient ozone and fine particle concentrations and population susceptibility among Canadian health regions
por: Stieb, David M., et al.
Publicado: (2019)

First Testing of Literature-Based Models for Predicting Increase in Body Weight and Adipose Tissue Mass After Kidney Transplantation
por: Schmid-Mohler, Gabriela, et al.
Publicado: (2022)

Comparison of All-Cause Mortality Between Canadian Kidney Transplant Recipients and Patients With Cancer: A Population-Based Cohort Study
por: Naylor, Kyla L., et al.
Publicado: (2021)

Public support for safer supply programs: analysis of a cross-sectional survey of Canadians in two provinces
por: Morris, Heather, et al.
Publicado: (2023)

Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
por: Reyes-Pardo, Humberto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_flaepkiudl6820hl43uou73nv3